Mechanisms of hepatocellular carcinoma progression
- PMID: 31148900
- PMCID: PMC6529884
- DOI: 10.3748/wjg.v25.i19.2279
Mechanisms of hepatocellular carcinoma progression
Abstract
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. It is the second leading cause of cancer-related deaths worldwide, with a very poor prognosis. In the United States, there has been only minimal improvement in the prognosis for HCC patients over the past 15 years. Details of the molecular mechanisms and other mechanisms of HCC progression remain unclear. Consequently, there is an urgent need for better understanding of these mechanisms. HCC is often diagnosed at advanced stages, and most patients will therefore need systemic therapy, with sorafenib being the most common at the present time. However, sorafenib therapy only minimally enhances patient survival. This review provides a summary of some of the known mechanisms that either cause HCC or contribute to its progression. Included in this review are the roles of viral hepatitis, non-viral hepatitis, chronic alcohol intake, genetic predisposition and congenital abnormalities, toxic exposures, and autoimmune diseases of the liver. Well-established molecular mechanisms of HCC progression such as epithelial-mesenchymal transition, tumor-stromal interactions and the tumor microenvironment, cancer stem cells, and senescence bypass are also discussed. Additionally, we discuss the roles of circulating tumor cells, immunomodulation, and neural regulation as potential new mechanisms of HCC progression. A better understanding of these mechanisms could have implications for the development of novel and more effective therapeutic and prognostic strategies, which are critically needed.
Keywords: Alcohol consumption; Cancer stem cells; Circulating tumor cells; Epithelial-mesenchymal transition; Hepatocellular carcinoma; Immunomodulation; Neural regulation; Tumor microenvironment; Tumor-stromal interactions; Viral/non-viral hepatitis.
Conflict of interest statement
Conflict-of-interest statement: Ogunwobi OO, Tan Y and Ma GX are supported by the National Cancer Institute grant number U54 CA221704(5). Ogunwobi OO is a Co-Founder of NucleoBio, Inc, a City University of New York biotechnology start-up company.
Figures


Similar articles
-
Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.Biomed Pharmacother. 2019 Jun;114:108864. doi: 10.1016/j.biopha.2019.108864. Epub 2019 Apr 10. Biomed Pharmacother. 2019. PMID: 30981107
-
Impaired function of CD4+ T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression.PLoS One. 2015 Feb 17;10(2):e0117458. doi: 10.1371/journal.pone.0117458. eCollection 2015. PLoS One. 2015. PMID: 25689070 Free PMC article.
-
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.Oncology. 2011;80(3-4):167-74. doi: 10.1159/000327591. Epub 2011 Jun 24. Oncology. 2011. PMID: 21701230
-
[Hepatocellular carcinoma].Ther Umsch. 2011 Apr;68(4):213-7. doi: 10.1024/0040-5930/a000153. Ther Umsch. 2011. PMID: 21452143 Review. German.
-
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.Gastroenterology. 2013 Mar;144(3):512-27. doi: 10.1053/j.gastro.2013.01.002. Epub 2013 Jan 9. Gastroenterology. 2013. PMID: 23313965 Free PMC article. Review.
Cited by
-
DNA Primase Subunit 1 Expression in Hepatocellular Carcinoma and Its Clinical Implication.Biomed Res Int. 2020 Aug 22;2020:9689312. doi: 10.1155/2020/9689312. eCollection 2020. Biomed Res Int. 2020. PMID: 32908930 Free PMC article.
-
Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment.Int J Mol Sci. 2021 Feb 11;22(4):1794. doi: 10.3390/ijms22041794. Int J Mol Sci. 2021. PMID: 33670268 Free PMC article. Review.
-
Synthesis and Characterization of Graphene Oxide/Polyethylene Glycol/Folic Acid/Brucine Nanocomposites and Their Anticancer Activity on HepG2 Cells.Int J Nanomedicine. 2024 Feb 5;19:1109-1124. doi: 10.2147/IJN.S445206. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38344441 Free PMC article.
-
Occult Hepatitis B Virus Infection in Hepatic Diseases and Its Significance for the WHO's Elimination Plan of Viral Hepatitis.Pathogens. 2024 Aug 6;13(8):662. doi: 10.3390/pathogens13080662. Pathogens. 2024. PMID: 39204261 Free PMC article. Review.
-
Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells.Sci Rep. 2022 Oct 25;12(1):17889. doi: 10.1038/s41598-022-21582-w. Sci Rep. 2022. PMID: 36284117 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous